A judge has rejected a bid by the applicants in two shareholder class actions against online fashion retailer Surfstitch to push forward with a proposed settlement of the cases without an opt-out notice to group members.
Motorola Solutions wants to amend its pleadings in an ongoing patent case against Shenzen-based Hytera Communications to add copyright claims relating to the source code for the radio devices at the centre of the dispute.
Rebel Wilson has lost a bid to have the High Court reconsider an appeals court’s decision to slash her record $4.75 million award in a defamation case against Bauer Media to $600,000.
A court on Thursday hit property spruiker We Buy Houses and its sole director, Richard ‘Rick’ Otton, with a record $18 million in total fines for misleading property investors with claims they could learn to buy real estate for $1.
Network 10 told a court Thursday it would “fiercely defend” a trade mark case brought by Fairfax Media over 10’s recent rebrand and its newly approved trade mark, 10 Boss.
A court has delivered a loss for Germany-based B. Braun Melsungen, dismissing its allegations that US-based device manufacturer Becton Dickinson infringed three of its intravenous catheter patents and ruling the patents invalid.
Maurice Blackburn’s battle with the Australian Taxation Office over a tax bill on class action settlements for thousands of Black Saturday bushfire victims went to court Tuesday, and the landmark case may turn on whether or not the law firm’s administration of the settlement distribution scheme counts as a business.
A judge has found the former director of Sydney-based insolvency practice CRS Warner Kugel is entitled to compensation after he was “ambushed” out of the firm in 2014.
The Federal Court has thrown out a proposed $35 million settlement between ASIC and Westpac over responsible lending breaches, saying the agreement was “unworkable” and left the court in an “information vacuum”.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.